Featured Research

from universities, journals, and other organizations

New target for prostate cancer resistant to anti-hormone therapies

Date:
April 23, 2014
Source:
University of Michigan Health System
Summary:
A new target that could remain sensitive even when prostate cancer becomes resistant to current treatments has been discovered by researchers. Prostate cancer becomes deadly when anti-hormone treatments stop working. This new study suggests a way to block the hormones at their entrance.

Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.

Researchers from the University of Michigan Comprehensive Cancer Center have found that a protein called BET bromodomain protein 4 binds to the hormone androgen receptor downstream of where current therapies work -- targeting androgen receptor signaling.

This could mean that when prostate cancer becomes resistant to current treatments, it might remain sensitive to a drug that targets BET bromodomain proteins. Results appear in Nature.

"We think we can target prostate cancer through androgen receptor signaling, rather than directly hitting the androgen receptor. These initial findings suggest the potential that a BET bromodomain inhibitor can work even when prostate cancer becomes resistant to anti-hormone therapies," says senior study author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at the University of Michigan Medical School.

The researchers used a compound called JQ1, designed to inhibit BET bromodomain proteins, to test the concept in cell lines and mice. They found that JQ1 blocked androgen signaling even when cells no longer responded to current anti-androgen therapies. The JQ1 BET bromodomain inhibitor blocked androgen receptor signaling, which is downstream of the androgen receptor, making it potentially unaffected by the acquired resistance related to hormone signaling.

The researchers also found that BET inhibitors appear to block several transcription factors, including the TMPRSS2-ERG gene fusion and MYC, known to drive prostate cancer.

Bromodomain inhibitors have been explored in blood cancers and a rare cancer called NUT midline carcinoma. This is one of the first indications that BET bromodomain inhibitors may be beneficial in a common solid tumor.

A newly formed company, OncoFusion Therapeutics, co-founded by Chinnaiyan and study co-author Shaomeng Wang, Ph.D., will look at developing potential BET bromodomain inhibitors to attack prostate cancer.

"BET bromodomain represents one of the most exciting targets in epigenetics," Chinnaiyan says. "Developing new ways to treat castration-resistant prostate cancer is critical to improving survival for this disease."


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke, Mathew K. Iyer, Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui S. Qin, Shaomeng Wang, Felix Y. Feng, Arul M. Chinnaiyan. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 2014; DOI: 10.1038/nature13229

Cite This Page:

University of Michigan Health System. "New target for prostate cancer resistant to anti-hormone therapies." ScienceDaily. ScienceDaily, 23 April 2014. <www.sciencedaily.com/releases/2014/04/140423132423.htm>.
University of Michigan Health System. (2014, April 23). New target for prostate cancer resistant to anti-hormone therapies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/04/140423132423.htm
University of Michigan Health System. "New target for prostate cancer resistant to anti-hormone therapies." ScienceDaily. www.sciencedaily.com/releases/2014/04/140423132423.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins